https://ons.digitellinc.com/p/cf/ons-congress-16
https://ons.digitellinc.com/p/s/immuno-oncology-landscape-what-does-the-future-hold-part-1-36
https://ons.digitellinc.com/p/s/assisting-patients-to-have-a-voice-in-their-care-roles-of-the-rnaprn-in-advance-care-planning-conversations-part-1-41
https://ons.digitellinc.com/p/s/cytogenetics-applications-of-genetic-testing-in-oncology-part-1-46
https://ons.digitellinc.com/p/s/surgical-oncology-enhanced-recovery-improves-outcomes-part-1-51
https://ons.digitellinc.com/p/s/the-psychiatric-patient-with-a-cancer-diagnosis-dual-treatment-strategies-part-1-56
https://ons.digitellinc.com/p/s/customizing-nursing-care-for-at-risk-family-members-in-cancer-caregiving-61
https://ons.digitellinc.com/p/s/dental-oncology-addressing-oral-care-rehabilitation-and-long-term-management-66
https://ons.digitellinc.com/p/s/ethical-dilemmas-advocating-for-your-patients-71
https://ons.digitellinc.com/p/s/what-is-in-a-name-biosimilars-in-oncology-practice-76
https://ons.digitellinc.com/p/s/it-is-a-matter-of-time-sepsis-in-oncology-practice-81
https://ons.digitellinc.com/p/s/cognitive-impairment-following-the-evidence-and-improving-quality-of-life-86
https://ons.digitellinc.com/p/s/pharmacokinetic-pk-directed-dosing-91
https://ons.digitellinc.com/p/s/leveraging-digital-health-as-an-aprn-part-1-96
https://ons.digitellinc.com/p/s/role-of-the-aprn-in-prescribing-oncologic-agents-101
https://ons.digitellinc.com/p/s/medical-marijuana-exploring-established-guidelines-for-aprns-certifying-a-medical-marijuana-condition-part-1-106
https://ons.digitellinc.com/p/s/thinking-beyond-the-current-roles-of-aprns-111
https://ons.digitellinc.com/p/s/telehealth-in-the-oncology-setting-dotting-the-is-and-crossing-the-ts-to-ensure-compliance-and-reimbursement-116
https://ons.digitellinc.com/p/s/patient-acuity-tools-in-the-outpatient-infusion-setting-how-to-make-them-work-for-you-121
https://ons.digitellinc.com/p/s/building-of-a-car-t-cell-program-how-to-go-from-none-to-done-126
https://ons.digitellinc.com/p/s/engaging-the-oncology-nurse-learner-with-technology-and-innovation-131
https://ons.digitellinc.com/p/s/am-i-an-oncology-nurse-yes-i-am-an-oncology-nurse-and-more-136
https://ons.digitellinc.com/p/s/building-an-oncology-inpatient-unit-staffing-educating-stabilizing-and-beyond-141
https://ons.digitellinc.com/p/s/creating-calm-during-calamity-lessons-in-leadership-146
https://ons.digitellinc.com/p/s/radiation-who-what-where-when-and-why-151
https://ons.digitellinc.com/p/s/beyond-the-beam-managing-radiation-therapy-side-effects-156
https://ons.digitellinc.com/p/s/emerging-therapies-in-radiation-from-a-medical-physics-perspective-161
https://ons.digitellinc.com/p/s/so-your-institution-wants-to-administer-radionuclides-166
https://ons.digitellinc.com/p/s/whisper-down-the-linac-is-the-existence-of-radiation-oncology-nursing-being-compromised-171
https://ons.digitellinc.com/p/s/prostate-cancer-overview-and-radiation-treatment-management-176
https://ons.digitellinc.com/p/s/innovative-methods-for-study-enrollment-181
https://ons.digitellinc.com/p/s/nih-funding-updates-186
https://ons.digitellinc.com/p/s/challenges-and-innovations-in-remote-oncology-research-study-visits-and-biometric-collection-part-2-191
https://ons.digitellinc.com/p/s/identifying-and-managing-germline-inherited-cancer-syndromes-part-1-196
https://ons.digitellinc.com/p/s/the-victoria-mock-new-investigator-award-lecture-201
https://ons.digitellinc.com/p/s/the-time-is-now-charting-the-course-to-achieve-health-equity-part-1-206
https://ons.digitellinc.com/p/s/aacrons-bench-to-bedside-brca12-and-beyond-risk-prediction-to-targeted-therapies-211
https://ons.digitellinc.com/p/s/spotlight-on-awards-the-ons-distinguished-researcher-lecture-216
https://ons.digitellinc.com/p/s/pharmacology-update-226
https://ons.digitellinc.com/p/s/pathway-to-resilience-for-oncology-nurses-during-a-pandemic-and-beyond-part-1-231
https://ons.digitellinc.com/p/s/closing-keynote-health-policy-session-with-us-representative-lauren-underwood-236
https://ons.digitellinc.com/p/s/phd-dnp-collaboration-opportunities-to-translate-scientific-research-into-practice-241
https://ons.digitellinc.com/p/s/disparities-improving-inclusion-of-underrepresented-populations-in-oncology-studies-246
https://ons.digitellinc.com/p/s/symptom-science-state-of-the-science-part-1-251
https://ons.digitellinc.com/p/s/symptom-science-precision-health-part-2-256
https://ons.digitellinc.com/p/s/challenges-and-innovations-in-remote-oncology-research-obtaining-e-consent-and-managing-ethics-part-1-261
https://ons.digitellinc.com/p/s/immuno-oncology-landscape-what-does-the-future-hold-part-2-266
https://ons.digitellinc.com/p/s/the-psychiatric-patient-with-a-cancer-diagnosis-dual-treatment-strategies-part-2-271
https://ons.digitellinc.com/p/s/assisting-patients-to-have-a-voice-in-their-care-roles-of-the-rnaprn-in-advanced-care-planning-conversations-part-2-276
https://ons.digitellinc.com/p/s/identifying-and-managing-germline-inherited-cancer-syndromes-part-2-281
https://ons.digitellinc.com/p/s/surgical-oncology-enhanced-recovery-improves-outcomes-part-2-286
https://ons.digitellinc.com/p/s/leveraging-digital-health-as-an-aprn-part-2-291
https://ons.digitellinc.com/p/s/mara-mogensen-flaherty-lectureship-collective-care-holding-burnout-grief-and-joy-through-the-arts-296
https://ons.digitellinc.com/p/s/cytogenetics-ethical-and-clinical-challenges-in-cancer-genomic-risk-assessment-part-2-301
https://ons.digitellinc.com/p/s/new-administration-new-us-congress-new-opportunities-for-nurses-to-be-advocates-306
https://ons.digitellinc.com/p/s/perception-is-reality-leveraging-the-value-of-certification-311
https://ons.digitellinc.com/p/s/ask-ons-oncology-nurses-address-your-clinical-questions-316
https://ons.digitellinc.com/p/s/medical-marijuana-the-role-of-an-aprn-certifying-a-medical-marijuana-condition-part-2-321
https://ons.digitellinc.com/p/s/a-showcase-of-nursing-innovation-326
https://ons.digitellinc.com/p/s/having-a-ball-a-healthy-dose-of-music-laughter-and-patient-inspiration-331
https://ons.digitellinc.com/p/s/vaccines-answering-our-questions-about-patients-with-cancer-and-covid-19-vaccines-336
https://ons.digitellinc.com/p/s/the-time-is-now-charting-the-course-to-achieve-health-equity-part-2-341
https://ons.digitellinc.com/p/s/education-breakout-sessions-349
https://ons.digitellinc.com/p/s/education-breakout-sessions-357
https://ons.digitellinc.com/p/s/education-breakout-sessions-364
https://ons.digitellinc.com/p/s/education-breakout-sessions-372
https://ons.digitellinc.com/p/s/education-breakout-sessions-374
https://ons.digitellinc.com/p/s/education-breakout-sessions-379
https://ons.digitellinc.com/p/s/education-breakout-sessions-387
https://ons.digitellinc.com/p/s/education-breakout-sessions-396
https://ons.digitellinc.com/p/s/education-breakout-sessions-403
https://ons.digitellinc.com/p/s/education-breakout-sessions-408
https://ons.digitellinc.com/p/s/education-breakout-sessions-416
https://ons.digitellinc.com/p/s/education-breakout-sessions-426
https://ons.digitellinc.com/p/s/education-breakout-sessions-433
https://ons.digitellinc.com/p/s/education-breakout-sessions-442
https://ons.digitellinc.com/p/s/education-breakout-sessions-447
https://ons.digitellinc.com/p/cf/test-collection-465
https://ons.digitellinc.com/p/s/test-webinar-472
https://ons.digitellinc.com/p/s/youve-got-this-test-488
https://ons.digitellinc.com/p/s/ons-awards-test-497
https://ons.digitellinc.com/p/s/opening-keynote-oncology-nursing-catalyzing-hope-and-care-505
https://ons.digitellinc.com/p/s/pathway-to-resilience-for-oncology-nurses-during-a-pandemic-and-beyond-part-2-510
https://ons.digitellinc.com/p/s/chakra-balancing-yoga-flow-517
https://ons.digitellinc.com/p/s/state-of-the-society-ons-business-meeting-523
https://ons.digitellinc.com/p/s/chakra-balancing-yoga-flow-encore-532
https://ons.digitellinc.com/p/s/gentle-chair-yoga-538
https://ons.digitellinc.com/p/s/gentle-chair-yoga-encore-544
https://ons.digitellinc.com/p/s/yoga-flow-and-lymphatic-face-massage-552
https://ons.digitellinc.com/p/s/yoga-flow-and-lymphatic-face-massage-encore-559
https://ons.digitellinc.com/p/s/restorative-yoga-and-sound-healing-meditation-567
https://ons.digitellinc.com/p/s/erleada-for-the-treatment-of-patients-with-mcspc-and-nmcrpc-575
https://ons.digitellinc.com/p/s/onco-nurse-academy-evolving-her2-treatment-approaches-across-tumor-types-580
https://ons.digitellinc.com/p/s/clinical-management-of-patients-with-cabometyx-r-cabozantinib-plus-opdivo-r-nivolumab-585
https://ons.digitellinc.com/p/s/real-world-nursing-scenarios-in-pancreatic-cancer-a-look-at-new-therapies-treatment-sequencing-and-patient-considerations-590
https://ons.digitellinc.com/p/s/actionable-mutations-within-nsclc-new-targets-and-new-treatments-595
https://ons.digitellinc.com/p/s/case-studies-in-multiple-myeloma-care-for-challenging-times-600
https://ons.digitellinc.com/p/s/therapeutic-advancements-in-myelodysplastic-syndromes-bridging-the-gap-between-patient-safety-and-quality-care-through-the-latest-science-and-evidence-based-learning-in-nursing-practice-605
https://ons.digitellinc.com/p/s/considerations-for-tailoring-treatment-for-first-line-and-relapsedrefractory-follicular-lymphoma-610
https://ons.digitellinc.com/p/s/oncology-nursing-showdown-aggressive-non-hodgkin-lymphoma-edition-615
https://ons.digitellinc.com/p/s/show-me-your-care-plan-nursing-strategies-to-individualize-cll-patient-care-in-the-context-of-recent-620
https://ons.digitellinc.com/p/s/reaction-in-action-strategies-to-effectively-manage-patients-with-anemia-on-iv-iron-therapy-625
https://ons.digitellinc.com/p/s/genomics-and-hematologic-malignancies-beyond-the-philadelphia-chromosome-630
https://ons.digitellinc.com/p/s/dissecting-the-decision-investigator-perspectives-on-key-issues-in-the-management-of-common-cancers-a-complimentary-ncpd-webinar-series-moderated-by-dr-neil-love-session-vi-hodgkin-and-non-hodgkin-lym-635
https://ons.digitellinc.com/p/s/dissecting-the-decision-investigator-perspectives-on-key-issues-in-the-management-of-common-cancers-a-complimentary-ncpd-webinar-series-moderated-by-dr-neil-love-session-xi-chimeric-antigen-receptor-t-640
https://ons.digitellinc.com/p/s/dissecting-the-decision-investigator-perspectives-on-key-issues-in-the-management-of-common-cancers-a-complimentary-ncpd-webinar-series-moderated-by-dr-neil-love-session-ii-non-small-cell-lung-cancer-645
https://ons.digitellinc.com/p/s/dissecting-the-decision-investigator-perspectives-on-key-issues-in-the-management-of-common-cancers-a-complimentary-ncpd-webinar-series-moderated-by-dr-neil-love-session-viii-gynecologic-cancers-650
https://ons.digitellinc.com/p/s/cure-extraordinary-healer-award-for-oncology-nursing-655
https://ons.digitellinc.com/p/s/dissecting-the-decision-investigator-perspectives-on-key-issues-in-the-management-of-common-cancers-a-complimentary-ncpd-webinar-series-moderated-by-dr-neil-love-session-v-prostate-cancer-660
https://ons.digitellinc.com/p/s/the-spectrum-of-mds-disease-management-and-patient-education-665
https://ons.digitellinc.com/p/s/dissecting-the-decision-investigator-perspectives-on-key-issues-in-the-management-of-common-cancers-a-complimentary-ncpd-webinar-series-moderated-by-dr-neil-love-session-x-chronic-lymphocytic-lymphoma-670
https://ons.digitellinc.com/p/s/dissecting-the-decision-investigator-perspectives-on-key-issues-in-the-management-of-common-cancers-a-complimentary-ncpd-webinar-series-moderated-by-dr-neil-love-session-i-breast-cancer-675
https://ons.digitellinc.com/p/s/dissecting-the-decision-investigator-perspectives-on-key-issues-in-the-management-of-common-cancers-a-complimentary-ncpd-webinar-series-moderated-by-dr-neil-love-session-vii-multiple-myeloma-680
https://ons.digitellinc.com/p/s/mpn-working-group-practical-applications-for-nurses-to-improve-patient-outcomes-and-next-steps-to-move-the-field-forward-685
https://ons.digitellinc.com/p/s/making-modern-treatment-choices-in-cll-oncology-nurse-insights-on-the-patient-journey-and-the-new-era-of-care-690
https://ons.digitellinc.com/p/s/advances-in-targeted-therapy-for-aml-practical-management-of-bcl-2-inhibitors-695
https://ons.digitellinc.com/p/s/cases-and-conversations-in-multiple-myeloma-nursing-considerations-for-managing-relapsedrefractory-disease-700
https://ons.digitellinc.com/p/s/updates-on-the-treatment-of-patients-with-unresectable-or-metastatic-her2-plus-breast-cancer-who-previously-received-anti-her2-therapies-705
https://ons.digitellinc.com/p/s/interactive-myeloma-clinic-nursing-pearls-for-current-and-emerging-therapies-710
https://ons.digitellinc.com/p/s/how-to-manage-patients-with-cll-receiving-a-bcl-2-inhibitor-case-based-discussions-715
https://ons.digitellinc.com/p/s/advocating-for-your-patient-real-world-biosimilar-experience-720
https://ons.digitellinc.com/p/s/navigating-novel-terrain-in-neurofibromatosis-type-1-an-interactive-road-map-for-the-oncology-nurse-in-the-era-of-targeted-therapy-725
https://ons.digitellinc.com/p/s/changing-times-in-dlbcl-oncology-nurse-insight-on-the-practicalities-of-antibody-therapy-730
https://ons.digitellinc.com/p/s/the-new-therapeutic-era-in-renal-cell-carcinoma-oncology-nursing-essentials-for-patient-care-735
https://ons.digitellinc.com/p/s/a-treatment-option-for-patients-with-myelodysplastic-syndromes-740
https://ons.digitellinc.com/p/s/a-newly-approved-anti-cd38-combination-for-the-treatment-of-multiple-myeloma-patients-as-early-as-first-relapse-745
https://ons.digitellinc.com/p/s/learn-more-about-an-fda-approved-treatment-for-metastatic-triple-negative-breast-cancer-750
https://ons.digitellinc.com/p/s/advancements-in-the-clinical-management-of-advanced-gastrointestinal-stromal-tumor-gist-755
https://ons.digitellinc.com/p/s/targeted-treatment-regimen-for-adult-patients-with-braf-mt-unresectable-or-metastatic-melanoma-760
https://ons.digitellinc.com/p/s/treatment-options-for-patients-with-lung-cancer-765
https://ons.digitellinc.com/p/s/educate-your-patients-on-imbruvica-r-ibrutinib-770
https://ons.digitellinc.com/p/s/guiding-patients-on-their-treatment-journey-with-ninlaro-r-ixazomib-775
https://ons.digitellinc.com/p/s/intervening-with-jakafi-r-ruxolitinib-to-achieve-durable-count-control-real-world-patient-case-discussion-focus-on-adults-with-polycythemia-vera-who-have-an-inadequate-response-to-hydroxyurea-780
https://ons.digitellinc.com/p/s/starting-and-taking-verzenio-r-abemaciclib-clinical-management-of-patients-with-hr-plus-her2-mbc-785
https://ons.digitellinc.com/p/s/an-evidence-based-approach-to-decreasing-vascular-access-complications-in-oncology-patients-790
https://ons.digitellinc.com/p/s/bringing-the-bedroom-to-the-bedside-discussing-sexuality-and-intimacy-795
https://ons.digitellinc.com/p/s/clinical-management-and-dose-modifications-with-an-immunomodulatory-treatment-in-relapsedrefractory-multiple-myeloma-800
https://ons.digitellinc.com/p/s/driving-innovation-in-the-treatment-of-solid-tumors-805
https://ons.digitellinc.com/p/s/exploring-a-treatment-option-for-patients-with-previously-treated-metastatic-small-cell-lung-cancer-sclc-810
https://ons.digitellinc.com/p/s/monjuvi-tafasitamab-cxix-for-use-as-second-line-therapy-in-adult-patients-with-rr-dlbcl-in-combination-with-lenalidomide-815
https://ons.digitellinc.com/p/s/a-discussion-of-efficacy-and-safety-on-a-treatment-option-for-adults-with-relapsed-or-refractory-rr-acute-lymphoblastic-leukemia-all-820
https://ons.digitellinc.com/p/s/prevention-of-chemotherapy-nausea-and-vomiting-cinv-a-case-based-presentation-825
https://ons.digitellinc.com/p/s/selecting-a-first-in-class-oral-therapy-for-patients-with-hr-plus-her2-metastatic-breast-cancer-830
https://ons.digitellinc.com/p/s/simplify-with-hemady-r-835
https://ons.digitellinc.com/p/s/treatment-options-for-the-management-of-patients-with-1l-arcc-840
https://ons.digitellinc.com/p/s/car-t-cell-therapy-the-science-and-the-patient-journey-845
https://ons.digitellinc.com/p/s/alunbrig-r-brigatinib-for-the-first-line-treatment-of-alk-plus-mnsclc-clinical-case-study-review-850
https://ons.digitellinc.com/p/s/clinical-considerations-for-nurses-when-administering-darzalex-faspro-r-855
https://ons.digitellinc.com/p/s/managing-immune-related-adverse-events-with-checkpoint-inhibitors-860
https://ons.digitellinc.com/p/s/nerlynx-r-neratinib-for-patients-with-her2-plus-breast-cancer-strategies-and-support-tools-to-achieve-durable-therapy-865
https://ons.digitellinc.com/p/s/cosela-a-novel-myeloprotection-therapy-870
https://ons.digitellinc.com/p/s/blenrep-belantamab-mafodotin-blmf-for-injection-100mg-875
https://ons.digitellinc.com/p/s/dissecting-the-decision-investigator-perspectives-on-key-issues-in-the-management-of-common-cancers-a-complimentary-ncpd-webinar-series-moderated-by-dr-neil-love-session-iii-acute-myeloid-leukemia-880
https://ons.digitellinc.com/p/s/dissecting-the-decision-investigator-perspectives-on-key-issues-in-the-management-of-common-cancers-a-complimentary-ncpd-webinar-series-moderated-by-dr-neil-love-session-iv-colorectal-and-gastroesopha-885
https://ons.digitellinc.com/p/s/dissecting-the-decision-investigator-perspectives-on-key-issues-in-the-management-of-common-cancers-a-complimentary-ncpd-webinar-series-moderated-by-dr-neil-love-session-ix-urothelial-bladder-carcinom-890
https://ons.digitellinc.com/p/s/xpovio-r-selinexor-now-approved-as-early-as-1st-relapse-in-multiple-myeloma-895
https://ons.digitellinc.com/p/s/ons-corporate-council-resource-video-bristol-myers-squibb-900
https://ons.digitellinc.com/p/s/ons-corporate-council-resource-video-eisai-905
https://ons.digitellinc.com/p/s/ons-corporate-council-resource-video-g1-therapeutics-910
https://ons.digitellinc.com/p/s/ons-corporate-council-resource-video-genentech-915
https://ons.digitellinc.com/p/s/ons-corporate-council-resource-video-janssen-and-johnson-and-johnson-920
https://ons.digitellinc.com/p/s/learning-hall-hours-925
https://ons.digitellinc.com/p/s/learning-hall-hours-930
https://ons.digitellinc.com/p/s/learning-hall-hours-935
https://ons.digitellinc.com/p/s/learning-hall-hours-940
https://ons.digitellinc.com/p/s/wellness-break-stress-resilience-in-challenging-times-sponsored-by-pfizer-945
https://ons.digitellinc.com/p/s/learning-hall-hours-950
https://ons.digitellinc.com/p/s/learning-hall-hours-955
https://ons.digitellinc.com/p/s/learning-hall-hours-960
https://ons.digitellinc.com/p/s/introducing-pepaxto-the-first-anticancer-peptide-drug-conjugate-for-the-management-of-multiple-myeloma-in-patients-who-have-received-at-least-4-prior-lines-and-are-triple-class-refractory-965
https://ons.digitellinc.com/p/s/seagen-inc-booth-presentation-970
https://ons.digitellinc.com/p/s/initiating-venclexta-treatment-in-patient-with-cll-975
https://ons.digitellinc.com/p/s/understanding-lung-cancer-980
https://ons.digitellinc.com/p/s/seagen-inc-booth-presentation-985
https://ons.digitellinc.com/p/s/initiating-venclexta-treatment-in-patient-with-cll-990
https://ons.digitellinc.com/p/s/combining-the-her2-plus-breast-cancer-antibodies-you-know-in-one-faster-mode-of-administration-995
https://ons.digitellinc.com/p/s/seagen-inc-booth-presentation-1000
https://ons.digitellinc.com/p/s/initiating-venclexta-treatment-in-patient-with-cll-1005
https://ons.digitellinc.com/p/s/genomic-medicine-for-oncology-practitioners-1010
https://ons.digitellinc.com/p/s/seagen-inc-booth-presentation-1015
https://ons.digitellinc.com/p/s/initiating-venclexta-treatment-in-patient-with-cll-1020
https://ons.digitellinc.com/p/s/my-patient-my-line-help-maintain-quality-care-in-patients-with-central-lines-1025
https://ons.digitellinc.com/p/s/a-treatment-option-for-patients-with-certain-types-of-advanced-tnbc-1033
https://ons.digitellinc.com/p/s/explore-a-treatment-option-for-certain-types-of-advanced-endometrial-carcinoma-1040
https://ons.digitellinc.com/p/s/monjuvi-tafasitamab-cxix-for-use-as-second-line-therapy-in-adult-patients-with-rr-dlbcl-in-combination-with-lenalidomide-1050
https://ons.digitellinc.com/p/s/monjuvi-tafasitamab-cxix-for-use-as-second-line-therapy-in-adult-patients-with-rr-dlbcl-in-combination-with-lenalidomide-1059
https://ons.digitellinc.com/p/s/advancement-in-the-1l-treatment-of-unresectable-or-metastatic-hcc-1065
https://ons.digitellinc.com/p/s/introduction-to-the-immune-system-1075
https://ons.digitellinc.com/p/s/monjuvi-tafasitamab-cxix-for-use-as-second-line-therapy-in-adult-patients-with-rr-dlbcl-in-combination-with-lenalidomide-1082
https://ons.digitellinc.com/p/s/monjuvi-tafasitamab-cxix-for-use-as-second-line-therapy-in-adult-patients-with-rr-dlbcl-in-combination-with-lenalidomide-1092
https://ons.digitellinc.com/p/s/clinical-overview-of-cabometyx-r-cabozantinib-and-opdivo-r-nivolumab-1101
https://ons.digitellinc.com/p/s/clinical-overview-of-cabometyx-r-cabozantinib-and-opdivo-r-nivolumab-1110
https://ons.digitellinc.com/p/s/testing-and-prognostic-factors-in-cll-1118
https://ons.digitellinc.com/p/s/the-role-of-nurses-in-guiding-clinical-decisions-through-comprehensive-molecular-testing-1127
https://ons.digitellinc.com/p/s/best-of-research-abstracts-1134
https://ons.digitellinc.com/p/s/research-abstract-critique-1144
https://ons.digitellinc.com/p/s/best-of-late-breaking-research-abstracts-1152
https://ons.digitellinc.com/p/s/industry-supported-symposia-1162
https://ons.digitellinc.com/p/s/industry-supported-symposia-1170
https://ons.digitellinc.com/p/s/industry-supported-symposia-1247
https://ons.digitellinc.com/p/s/re-wined-wine-down-with-ons-and-beigene-1421
https://ons.digitellinc.com/p/cf/2021-ons-bridge-1437
https://ons.digitellinc.com/p/s/safe-and-effective-use-of-opioids-to-treat-cancer-pain-1438
https://ons.digitellinc.com/p/s/bridging-the-gap-creating-effective-virtual-education-1443
https://ons.digitellinc.com/p/s/genitourinary-cancer-diagnosis-treatment-multidisciplinary-care-coordination-1448
https://ons.digitellinc.com/p/s/measuring-the-impact-of-nurse-navigation-1453
https://ons.digitellinc.com/p/s/continuing-the-conversation-a-panel-discussion-on-racism-in-nursing-1458
https://ons.digitellinc.com/p/s/from-guidelines-to-practice-what-nurses-need-to-know-1463
https://ons.digitellinc.com/p/s/dimensions-of-surgical-oncology-nursing-overview-of-specialty-patient-preparedness-pre-and-post-operative-management-1468
https://ons.digitellinc.com/p/s/only-the-best-for-the-us-how-does-americas-healthcare-system-compare-in-the-global-marketplace-1473
https://ons.digitellinc.com/p/s/overview-of-vascular-access-devices-1478
https://ons.digitellinc.com/p/s/opioid-stewardship-in-cancer-care-a-system-initiative-1483
https://ons.digitellinc.com/p/s/the-long-and-the-short-of-it-monitoring-immune-related-toxicity-across-the-cancer-continuum-1488
https://ons.digitellinc.com/p/s/bridging-the-digital-divide-in-clinical-care-1493
https://ons.digitellinc.com/p/s/multiple-myeloma-updates-in-treatment-1498
https://ons.digitellinc.com/p/s/patient-programming-1503
https://ons.digitellinc.com/p/s/electrolyte-replacement-in-outpatient-oncology-1508
https://ons.digitellinc.com/p/s/clinical-and-administrative-challenges-and-triumphs-during-a-global-pandemic-developing-paradigms-for-clinical-response-and-efficiency-1513
https://ons.digitellinc.com/p/s/a-foundation-in-genetics-and-genomics-enhancing-the-knowledge-of-the-oncology-nurse-1518
https://ons.digitellinc.com/p/s/digital-health-in-oncology-care-innovation-and-implications-beyond-covid-1523
https://ons.digitellinc.com/p/s/psychiatric-disorders-in-cancer-1528
https://ons.digitellinc.com/p/s/oncology-nurses-got-resilience-1533
https://ons.digitellinc.com/p/s/the-endocrine-system-implications-in-oncology-1538
https://ons.digitellinc.com/p/s/ambulatory-infusion-a-panel-discussion-of-approaches-to-staffing-1543
https://ons.digitellinc.com/p/s/opening-keynote-addressing-racism-in-nursing-accountability-and-action-1545
https://ons.digitellinc.com/p/s/the-secret-saucethriving-in-times-of-change-1550
https://ons.digitellinc.com/p/s/considerations-for-tailoring-treatment-for-first-line-and-relapsedrefractory-follicular-lymphoma-1565
https://ons.digitellinc.com/p/s/blenrep-rems-real-world-implementation-and-best-practices-1570
https://ons.digitellinc.com/p/s/a-treatment-option-for-patients-with-myelodysplastic-syndromes-1595
https://ons.digitellinc.com/p/s/cosela-a-novel-myeloprotection-therapy-1600
https://ons.digitellinc.com/p/s/monjuvi-tafasitamab-cxix-for-use-as-second-line-therapy-in-adult-patients-with-rr-dlbcl-in-combination-with-lenalidomide-1605
https://ons.digitellinc.com/p/s/advancements-in-biomarker-directed-therapies-for-non-small-cell-lung-cancer-1610
https://ons.digitellinc.com/p/s/targeted-treatment-regimen-for-adult-patients-with-braf-mt-unresectable-or-metastatic-melanoma-1640
https://ons.digitellinc.com/p/s/clinical-management-of-1l-advanced-rcc-patients-on-cabometyx-r-plus-opdivo-r-1645
https://ons.digitellinc.com/p/s/advancements-in-the-clinical-management-of-advanced-gastrointestinal-stromal-tumor-gist-1650
https://ons.digitellinc.com/p/s/workstation-ergonomics-1660
https://ons.digitellinc.com/p/s/intention-setting-1665
https://ons.digitellinc.com/p/s/chair-yoga-1670
https://ons.digitellinc.com/p/s/guided-meditation-1675
https://ons.digitellinc.com/p/s/erleada-for-the-treatment-of-patients-with-metastatic-castration-sensitive-prostate-cancer-mcspc-and-non-metastatic-castration-resistant-prostate-cancer-nmcrpc-1683
https://ons.digitellinc.com/p/s/experts-introduce-biomarker-testing-a-video-mini-series-1688
https://ons.digitellinc.com/p/s/bridge-101-1693
https://ons.digitellinc.com/p/s/experts-introduce-biomarker-testing-liquid-biopsy-1698
https://ons.digitellinc.com/p/s/experts-introduce-biomarker-testing-paired-somatic-and-germline-testing-1703
https://ons.digitellinc.com/p/s/experts-introduce-biomarker-testing-germline-testing-1708
https://ons.digitellinc.com/p/s/experts-introduce-biomarker-testing-biomarker-basics-1713
https://ons.digitellinc.com/p/s/coffee-break-with-platinum-and-gold-exhibitors-1715
https://ons.digitellinc.com/p/s/learning-hall-hours-1717
https://ons.digitellinc.com/p/s/coffee-break-with-platinum-and-gold-exhibitors-1719
https://ons.digitellinc.com/p/s/learning-hall-hours-1720
https://ons.digitellinc.com/p/s/coffee-break-with-platinum-and-gold-exhibitors-1725
https://ons.digitellinc.com/p/s/learning-hall-hours-1729
https://ons.digitellinc.com/p/s/myovant-sciences-and-pfizer-inc-introducing-an-oral-treatment-option-for-advanced-prostate-cancer-1734
https://ons.digitellinc.com/p/s/erleada-for-the-treatment-of-patients-with-metastatic-castration-sensitive-prostate-cancer-mcspc-and-non-metastatic-castration-resistant-prostate-cancer-nmcrpc-1739
https://ons.digitellinc.com/p/s/raising-awareness-what-the-patient-care-team-should-know-about-metastatic-non-small-lung-cancer-nsclc-with-egfr-exon-20-insertion-mutations-1744
https://ons.digitellinc.com/p/s/understanding-lung-cancer-1749
https://ons.digitellinc.com/p/s/my-patient-my-line-help-maintain-quality-care-in-patients-with-central-lines-1754
https://ons.digitellinc.com/p/s/biology-and-treatment-of-breast-cancer-1759
https://ons.digitellinc.com/p/s/wellness-break-work-from-home-workstation-ergonomics-1764
https://ons.digitellinc.com/p/s/wellness-break-intention-setting-1768
https://ons.digitellinc.com/p/s/wellness-break-guided-meditation-1770
https://ons.digitellinc.com/p/s/wellness-break-chair-yoga-1774
https://ons.digitellinc.com/p/cf/ons-corporate-council-resources-1775
https://ons.digitellinc.com/p/s/g1-cc-moa-video-1777
https://ons.digitellinc.com/p/s/regeneron-corpcouncil-chris-and-ken-testimonial-v5-hi-res-1779
https://ons.digitellinc.com/p/s/regeneron-corpcouncil-bill-and-cathie-testimonial-v7-hi-res-1782
https://ons.digitellinc.com/p/s/lynparza-hcp-2021-ct-onelyn-merck-az-hype-video-update-2-3-1783
https://ons.digitellinc.com/p/s/lenv-us5090-hcc-video-1784
https://ons.digitellinc.com/p/s/lenv-us5156-lenvima-rcc-video-dec-isi-2020-update-1-1785
https://ons.digitellinc.com/p/s/lenv-us5176-dtc-video-dec-2020-isi-update-1787
https://ons.digitellinc.com/p/s/adus-gswny-cl-104107-039-onureg-gpo-video-update-v102mp4-1789
https://ons.digitellinc.com/p/s/reblozyl-mds-videomp4-1790
https://ons.digitellinc.com/p/s/survivorship-today-amanda-ditl-videomp4-1795
https://ons.digitellinc.com/p/s/us-25586-crt-unbranded-group-video-nsclc-ae-management-general-1797
https://ons.digitellinc.com/p/s/us-25596-unbranded-onc-crt-group-video-nsclc-addressing-patient-concerns-about-crt-toxicities-1799
https://ons.digitellinc.com/p/s/genentech-the-importance-of-cancer-screening-1800
https://ons.digitellinc.com/p/s/hala-us3370-virtual-booth-halaven-video-os-claim-update-1805
https://ons.digitellinc.com/p/s/general-1808
https://ons.digitellinc.com/p/cf/2022-ons-bridge-1822
https://ons.digitellinc.com/p/s/welcome-and-keynote-address-bringing-joy-and-meaning-back-to-your-work-1834
https://ons.digitellinc.com/p/s/clinical-trials-on-the-frontline-the-changing-landscape-of-clinical-trials-nursing-1835
https://ons.digitellinc.com/p/s/navigation-and-the-evolution-of-the-nurse-navigator-role-1836
https://ons.digitellinc.com/p/s/biosimilars-how-do-you-explain-them-to-your-patients-1837
https://ons.digitellinc.com/p/s/aya-difficult-but-necessary-topics-1838
https://ons.digitellinc.com/p/s/radiation-safety-how-much-is-too-much-1839
https://ons.digitellinc.com/p/s/application-of-tumor-variants-in-clinical-practice-1840
https://ons.digitellinc.com/p/s/cannabinoids-for-patients-with-cancer-1841
https://ons.digitellinc.com/p/s/abcs-of-biosimilars-authorization-billing-and-coding-1842
https://ons.digitellinc.com/p/s/car-t-enhancing-the-nursing-perspective-1843
https://ons.digitellinc.com/p/s/telehealth-do-you-see-me-now-part-1-1845
https://ons.digitellinc.com/p/s/helping-your-patients-find-their-voice-1846
https://ons.digitellinc.com/p/s/beyond-blood-counts-and-chemistries-the-clinical-significance-of-those-other-labs-1847
https://ons.digitellinc.com/p/s/oncologic-emergencies-and-immune-related-adverse-events-iraes-whats-the-difference-1848
https://ons.digitellinc.com/p/s/staying-current-during-constant-change-1849
https://ons.digitellinc.com/p/s/long-term-issuescgvhd-chronic-graft-vs-host-disease-and-long-term-follow-up-1850
https://ons.digitellinc.com/p/s/telehealth-we-heard-we-saw-but-did-we-conquer-part-2-1851
https://ons.digitellinc.com/p/s/finding-your-voice-how-nurses-can-create-a-healthy-work-culture-to-enhance-a-thriving-work-environment-1852
https://ons.digitellinc.com/p/s/managing-oral-cancer-therapies-what-are-your-tools-1853
https://ons.digitellinc.com/p/s/climate-change-and-its-impact-on-health-1854
https://ons.digitellinc.com/p/s/ask-oncology-nursing-certification-corporation-your-certification-questions-1855
https://ons.digitellinc.com/p/s/assessment-tools-and-implications-for-practice-1856
https://ons.digitellinc.com/p/s/distress-screening-how-are-you-doing-1857
https://ons.digitellinc.com/p/s/ask-the-ons-clinical-team-your-practice-question-1858
https://ons.digitellinc.com/p/s/learn-how-the-oncology-nursing-foundation-can-support-your-professional-growth-1859
https://ons.digitellinc.com/p/s/discharge-follow-up-and-its-benefits-1860
https://ons.digitellinc.com/p/s/learn-how-ons-supports-your-institution-1861
https://ons.digitellinc.com/p/s/chat-with-the-ons-board-of-directors-1862
https://ons.digitellinc.com/p/s/learn-how-ons-supports-your-institution-1863
https://ons.digitellinc.com/p/s/using-technology-to-enhance-patient-care-1864
https://ons.digitellinc.com/p/s/continuing-the-conversation-climate-change-and-its-impact-on-health-1865
https://ons.digitellinc.com/p/s/patient-education-follow-up-education-after-the-first-teach-1866
https://ons.digitellinc.com/p/s/lets-talk-genomics-and-your-practice-1867
https://ons.digitellinc.com/p/s/ask-oncology-nursing-certification-corporation-your-certification-questions-1868
https://ons.digitellinc.com/p/s/evidence-based-practice-overview-1869
https://ons.digitellinc.com/p/s/talk-with-the-ons-leadership-development-committee-1870
https://ons.digitellinc.com/p/s/continuing-the-conversation-keynote-bringing-joy-and-meaning-back-to-your-work-1871
https://ons.digitellinc.com/p/cf/corporate-council-resources-2022-1872
https://ons.digitellinc.com/packages/59/view
https://ons.digitellinc.com/p/s/abbvie-1874
https://ons.digitellinc.com/p/s/ons-bridge-101-1875
https://ons.digitellinc.com/p/s/physicians-education-resource-cases-and-conversations-nursing-considerations-for-the-management-of-er-plus-breast-cancer-1876
https://ons.digitellinc.com/p/s/bristol-myers-squibb-treatment-options-for-patients-with-unresectable-or-metastatic-melanoma-1877
https://ons.digitellinc.com/p/s/incyte-jakafi-real-world-case-discussion-when-to-intervene-with-jakafi-r-ruxolitinib-in-adults-with-polycythemia-vera-who-have-an-inadequate-response-to-hydroxyurea-1878
https://ons.digitellinc.com/p/s/genentech-strategies-for-recognizing-burnout-and-building-resilience-1879
https://ons.digitellinc.com/p/s/janssen-biotech-inc-egfr-exon-20-insertion-mutations-considerations-for-the-patient-care-team-in-the-management-and-treatment-of-adult-patients-with-locally-advanced-or-metastatic-egfr-plus-non-small--1880
https://ons.digitellinc.com/p/s/physicians-education-resource-onco-nurse-academy-exploring-an-advent-of-targeted-therapies-across-advanced-nsclc-care-and-strategies-for-managing-adverse-events-associated-with-treatment-1881
https://ons.digitellinc.com/p/s/physicians-education-resource-nursing-management-of-relapsedrefractory-multiple-myeloma-in-an-era-of-expanding-options-1882
https://ons.digitellinc.com/p/s/bristol-myers-squibb-treatment-options-for-patients-with-resectable-and-metastatic-non-small-cell-lung-cancer-1883
https://ons.digitellinc.com/p/s/incyte-jakafi-intervene-with-jakafi-r-ruxolitinib-at-the-first-sign-of-initial-systemic-treatment-failure-in-chronic-gvhd-a-real-world-case-based-resource-for-advanced-practice-professionals-1884
https://ons.digitellinc.com/p/s/g1-therapeutics-cosela-a-novel-myeloprotection-1885
https://ons.digitellinc.com/p/s/astrazeneca-best-practices-precision-medicine-in-oncology-nursing-1886
https://ons.digitellinc.com/p/cf/2023-ons-bridge-1889
https://ons.digitellinc.com/p/s/opening-and-keynote-address-finding-your-why-1890
https://ons.digitellinc.com/p/s/caring-for-patients-with-uncommon-diagnoses-1891
https://ons.digitellinc.com/p/s/maintaining-and-assessing-nursing-competency-in-new-and-experienced-nurses-1892
https://ons.digitellinc.com/p/s/pain-management-safe-opioid-use-and-alternative-pain-management-therapies-1893
https://ons.digitellinc.com/p/s/checkpoint-inhibitors-part-2-side-effect-etiology-and-management-1895
https://ons.digitellinc.com/p/s/interventional-radiology-not-just-line-placement-1896
https://ons.digitellinc.com/p/s/reactions-and-desensitization-1897
https://ons.digitellinc.com/p/s/caring-for-vulnerable-populations-1898
https://ons.digitellinc.com/p/s/re-defining-the-bell-recognizing-milestones-1900
https://ons.digitellinc.com/p/s/palliative-care-timing-matters-1901
https://ons.digitellinc.com/p/s/checkpoint-inhibitors-part-1-whats-on-the-horizon-1902
https://ons.digitellinc.com/p/s/rebuilding-strong-teams-finding-the-pathway-back-from-stress-injury-1903
https://ons.digitellinc.com/p/s/genomics-101-1904
https://ons.digitellinc.com/p/s/transgender-persons-with-cancer-what-can-we-do-better-1905
https://ons.digitellinc.com/p/s/conversations-surrounding-fertility-preservation-how-to-best-serve-and-support-our-patients-1906
https://ons.digitellinc.com/p/s/caring-for-oncology-patients-with-physical-disabilities-1907
https://ons.digitellinc.com/p/s/recognizing-and-managing-non-physical-violence-in-the-workplace-1908
https://ons.digitellinc.com/p/s/the-impact-of-implicit-bias-on-the-care-of-people-with-cancer-1909
https://ons.digitellinc.com/p/s/learn-more-about-oncc-certification-1910
https://ons.digitellinc.com/p/s/overcome-staffing-challenges-1911
https://ons.digitellinc.com/p/s/the-oncology-nursing-foundation-can-fund-your-education-conference-attendance-and-more-1912
https://ons.digitellinc.com/p/s/ask-the-experts-get-answers-to-your-clinical-questions-1913
https://ons.digitellinc.com/p/s/ons-board-of-directors-town-hall-1914
https://ons.digitellinc.com/p/s/enhance-your-leadership-skills-today-1915
https://ons.digitellinc.com/p/s/crucial-conversations-in-rr-multiple-myeloma-nursing-strategies-to-optimize-patient-communication-and-improve-outcomes-1916
https://ons.digitellinc.com/p/s/taking-a-critical-look-at-healthcare-inequity-among-patients-with-cancer-what-role-do-onco-nurses-play-1917
https://ons.digitellinc.com/p/s/medical-crossfire-r-what-are-effective-strategies-for-onco-nurses-to-improve-outcomes-in-patients-with-small-cell-lung-cancer-1918
https://ons.digitellinc.com/p/s/treatment-options-for-patients-with-resectable-and-metastatic-non-small-cell-lung-cancer-1919
https://ons.digitellinc.com/p/s/treatment-options-for-patients-with-unresectable-or-metastatic-melanoma-1920
https://ons.digitellinc.com/p/s/explore-data-for-an-fda-approved-treatment-option-in-hr-plus-her2-breast-cancer-in-certain-adjuvant-or-metastatic-settings-1921
https://ons.digitellinc.com/p/s/case-based-learnings-on-a-treatment-approach-for-certain-patients-with-high-risk-nmibc-webcast-1922
https://ons.digitellinc.com/p/s/the-value-of-certification-recent-research-that-makes-the-case-1923
https://ons.digitellinc.com/p/cf/2024-ons-bridge-1925
https://ons.digitellinc.com/p/s/welcome-and-keynote-1927
https://ons.digitellinc.com/p/s/vascular-access-best-practices-guidelines-and-troubleshooting-1928
https://ons.digitellinc.com/p/s/roadmaps-for-care-understanding-treatment-guidelines-1929
https://ons.digitellinc.com/p/s/virtual-reality-to-manage-anxiety-during-treatment-1930
https://ons.digitellinc.com/p/s/interventional-oncology-and-liver-directed-therapies-1931
https://ons.digitellinc.com/p/s/radiation-oncology-just-the-facts-1932
https://ons.digitellinc.com/p/s/quality-improvement-at-the-frontlines-1933
https://ons.digitellinc.com/p/s/time-is-of-the-essence-managing-metabolic-oncologic-emergencies-1934
https://ons.digitellinc.com/p/s/meeting-the-needs-of-adolescent-and-young-adults-in-oncology-1935
https://ons.digitellinc.com/p/s/navigating-the-role-of-nurse-navigators-1936
https://ons.digitellinc.com/p/s/dont-miss-the-signs-managing-structural-oncologic-emergencies-1937
https://ons.digitellinc.com/p/s/lab-monitoring-102-1938
https://ons.digitellinc.com/p/s/difficult-conversations-part-1-practical-approaches-1939
https://ons.digitellinc.com/p/s/considerations-for-bispecific-antibody-t-cell-engager-therapy-1940
https://ons.digitellinc.com/p/s/treatment-updates-in-acute-leukemia-1941
https://ons.digitellinc.com/p/s/difficult-conversations-part-2-navigating-emotional-challenges-1942
https://ons.digitellinc.com/p/s/navigating-usp-800-and-best-practices-for-safe-handling-of-hazardous-agents-1943
https://ons.digitellinc.com/p/s/mastering-the-art-of-nursing-telephone-triage-for-the-cancer-patient-1944
https://ons.digitellinc.com/p/s/head-and-neck-cancer-managing-a-complex-treatment-regimen-1945
https://ons.digitellinc.com/p/s/silent-partners-in-health-care-1946
https://ons.digitellinc.com/p/s/discover-your-professional-home-insights-from-ons-board-members-1947
https://ons.digitellinc.com/p/s/celebrating-yesterday-transforming-tomorrow-fifty-years-of-oncology-nursing-excellence-1948
https://ons.digitellinc.com/p/s/fund-your-education-conference-attendance-and-more-through-the-oncology-nursing-foundation-1949
https://ons.digitellinc.com/p/s/ask-ons-show-and-tell-1950
https://ons.digitellinc.com/p/s/learn-more-about-oncc-certification-1951
https://ons.digitellinc.com/p/s/enhance-your-leadership-skills-with-ons-1952
https://ons.digitellinc.com/p/s/nurses-in-advocacy-how-to-make-a-difference-locally-and-nationally-1953
https://ons.digitellinc.com/p/s/myelofibrosis-and-strategies-for-disease-management-key-considerations-for-patient-care-gsk-medical-affairs-1954
https://ons.digitellinc.com/p/s/immunotherapy-for-nmsc-key-insights-for-oncology-dermatology-and-infusion-nurses-provided-by-rmei-medical-education-llc-and-supported-by-an-independent-medical-education-grant-from-regeneron-pharmaceu-1955
https://ons.digitellinc.com/p/s/treatment-options-for-patients-with-resectable-or-metastatic-non-small-cell-lung-cancer-bristol-myers-squibb-1956
https://ons.digitellinc.com/p/s/explore-the-current-data-that-could-help-you-recognizeassess-candidates-for-a-cdk4-and-6-inhibitor-eli-lilly-1957
https://ons.digitellinc.com/p/s/identification-and-management-of-oncologic-emergencies-astrazeneca-1958
https://ons.digitellinc.com/p/s/practicing-resilience-in-your-daily-life-1959
https://ons.digitellinc.com/p/s/unleashing-the-power-of-artificial-intelligence-in-oncology-nursing-1960
https://ons.digitellinc.com/p/s/a-bispecific-antibody-treatment-option-in-relapsed-refractory-multiple-myeloma-johnson-and-johnson-1961
https://ons.digitellinc.com/p/s/the-role-of-the-oncology-nurse-in-the-management-of-adverse-events-and-patient-compliance-for-gastricgej-cancer-patients-on-claudin182-targeting-agents-astellas-1962